AU2013272701B2 - Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors - Google Patents

Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors Download PDF

Info

Publication number
AU2013272701B2
AU2013272701B2 AU2013272701A AU2013272701A AU2013272701B2 AU 2013272701 B2 AU2013272701 B2 AU 2013272701B2 AU 2013272701 A AU2013272701 A AU 2013272701A AU 2013272701 A AU2013272701 A AU 2013272701A AU 2013272701 B2 AU2013272701 B2 AU 2013272701B2
Authority
AU
Australia
Prior art keywords
group
imidazo
phenyl
pyridazin
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013272701A
Other languages
English (en)
Other versions
AU2013272701A2 (en
AU2013272701A1 (en
Inventor
Yoshito HAMADA
Yoshiko Kagoshima
Masaki Kiga
Yasuyuki Takeda
Ryoichi Tanaka
Yuichi Tominaga
Yuko Yamamoto
Kenji Yoshikawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of AU2013272701A1 publication Critical patent/AU2013272701A1/en
Publication of AU2013272701A2 publication Critical patent/AU2013272701A2/en
Application granted granted Critical
Publication of AU2013272701B2 publication Critical patent/AU2013272701B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2013272701A 2012-06-04 2013-06-03 Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors Active AU2013272701B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012-127079 2012-06-04
JP2012127079 2012-06-04
PCT/JP2013/065328 WO2013183578A1 (ja) 2012-06-04 2013-06-03 キナーゼ阻害剤としてのイミダゾ[１，２－ｂ]ピリダジン誘導体

Publications (3)

Publication Number Publication Date
AU2013272701A1 AU2013272701A1 (en) 2015-01-15
AU2013272701A2 AU2013272701A2 (en) 2015-01-22
AU2013272701B2 true AU2013272701B2 (en) 2017-12-21

Family

ID=49711970

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013272701A Active AU2013272701B2 (en) 2012-06-04 2013-06-03 Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors

Country Status (32)

Country Link
US (2) US9187489B2 (OSRAM)
EP (1) EP2857404B1 (OSRAM)
JP (1) JP5814467B2 (OSRAM)
KR (1) KR101781255B1 (OSRAM)
CN (1) CN104520300B (OSRAM)
AU (1) AU2013272701B2 (OSRAM)
BR (1) BR112014029851B1 (OSRAM)
CA (1) CA2874819C (OSRAM)
CO (1) CO7160119A2 (OSRAM)
CY (1) CY1119607T1 (OSRAM)
DK (1) DK2857404T3 (OSRAM)
ES (1) ES2648228T3 (OSRAM)
HR (1) HRP20171724T1 (OSRAM)
HU (1) HUE037221T2 (OSRAM)
IL (1) IL236075A (OSRAM)
IN (1) IN2014MN02497A (OSRAM)
LT (1) LT2857404T (OSRAM)
MX (1) MX357021B (OSRAM)
MY (1) MY170326A (OSRAM)
NO (1) NO2857404T3 (OSRAM)
NZ (1) NZ702574A (OSRAM)
PH (1) PH12014502721B1 (OSRAM)
PL (1) PL2857404T3 (OSRAM)
PT (1) PT2857404T (OSRAM)
RS (1) RS56625B1 (OSRAM)
RU (1) RU2635917C2 (OSRAM)
SG (1) SG11201408052WA (OSRAM)
SI (1) SI2857404T1 (OSRAM)
SM (1) SMT201700539T1 (OSRAM)
TW (1) TWI585088B (OSRAM)
WO (1) WO2013183578A1 (OSRAM)
ZA (1) ZA201408843B (OSRAM)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2350075B1 (en) 2008-09-22 2014-03-05 Array Biopharma, Inc. Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
KR101853026B1 (ko) 2008-10-22 2018-04-27 어레이 바이오파마 인크. ＴＲＫ 키나아제 억제제로서 치환된 피라졸로［１,５­ａ］ 피리미딘 화합물
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
CN105693720B (zh) 2010-05-20 2019-01-18 阵列生物制药公司 作为trk激酶抑制剂的大环化合物
CA2872645A1 (en) 2012-05-30 2013-12-05 Nippon Shinyaku Co., Ltd. Aromatic heterocyclic derivative and pharmaceutical
AU2015238298B2 (en) * 2014-03-27 2019-04-18 Janssen Pharmaceutica Nv Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrimidine derivatives and 2,3-dihydro-1H-imidazo[1,2-b]pyrazole derivatives as ROS1 inhibitors
EA032255B1 (ru) * 2014-03-27 2019-04-30 Янссен Фармацевтика Нв ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 4,5,6,7-ТЕТРАГИДРОПИРАЗОЛО[1,5-a]ПИРАЗИНА И ПРОИЗВОДНЫЕ 5,6,7,8-ТЕТРАГИДРО-4H-ПИРАЗОЛО[1,5-a][1,4]ДИАЗЕПИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Ros1
EP3134084B1 (en) * 2014-04-25 2021-03-17 Exelixis, Inc. Method of treating lung adenocarcinoma
TWI746426B (zh) 2014-11-16 2021-11-21 美商亞雷生物製藥股份有限公司 (S)-N-(5-((R)-2-(2,5-二氟苯基)-吡咯啶-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羥基吡咯啶-1-甲醯胺硫酸氫鹽結晶型
KR20180021745A (ko) 2015-06-01 2018-03-05 록쏘 온콜로지, 인코포레이티드 암을 진단하고 치료하는 방법
US10919875B2 (en) 2015-06-18 2021-02-16 89Bio Ltd Substituted 4-benzyl and 4-benzoyl piperidine derivatives
ES2821049T3 (es) 2015-06-18 2021-04-23 89Bio Ltd Derivados de piperidina 1,4 sustituidos
EP3322706B1 (en) 2015-07-16 2020-11-11 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
TN2018000138A1 (en) 2015-10-26 2019-10-04 Array Biopharma Inc Point mutations in trk inhibitor-resistant cancer and methods relating to the same
CN106854174A (zh) * 2015-12-08 2017-06-16 湖南华腾制药有限公司 一种4位取代哌啶衍生物的制备方法
RS65988B1 (sr) 2016-04-04 2024-10-31 Loxo Oncology Inc Postupak lečenja pedijatrijskih karcinoma
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
HUE068971T2 (hu) 2016-04-04 2025-02-28 Loxo Oncology Inc (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-A]pirimidin-3-il) -3-hidroxipirrolidin-1-karboxamid folyékony készítményei
SI3458456T1 (sl) 2016-05-18 2021-04-30 Loxo Oncology, Inc. Priprava (S)-N-(5-((R)-2-(2,5-difluorofenil) pirolidin-1-il) pirazolo (1,5-A) pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida
CN107400082A (zh) * 2016-05-19 2017-11-28 湖南华腾制药有限公司 一种取代哌啶衍生物的制备方法
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190072A1 (ar) * 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
CN110267960B (zh) 2017-01-18 2022-04-26 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
CA3055504A1 (en) * 2017-03-14 2018-09-20 Daiichi Sankyo Company, Limited Method for producing 3,6-disubstituted imidazo[1,2-b]pyridazine derivative
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
EP3700576A1 (en) 2017-10-26 2020-09-02 Array Biopharma Inc. Formulations of a macrocyclic trk kinase inhibitor
CN109748902B (zh) * 2017-11-02 2020-11-06 杭州科巢生物科技有限公司 一种盐酸安罗替尼的制备方法
US12077599B2 (en) 2017-11-29 2024-09-03 Seoul National University R&Db Foundation, National Cancer Center Anti-ROS1 antibody and use thereof
CN108129288B (zh) * 2017-12-27 2021-01-22 上海毕得医药科技股份有限公司 一种反式-3-羟基环丁基甲酸的合成方法
WO2019143994A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
TW201938169A (zh) 2018-01-18 2019-10-01 美商亞雷生物製藥股份有限公司 作為RET激酶抑制劑之經取代吡唑并[3,4-d]嘧啶化合物
CN111971286B (zh) 2018-01-18 2023-04-14 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物
CA3095366A1 (en) 2018-03-29 2019-10-03 Loxo Oncology, Inc. Treatment of trk-associated cancers
EP3827009A4 (en) 2018-07-24 2022-04-27 Taiho Pharmaceutical Co., Ltd. HETEROBICYCLIC COMPOUNDS TO INHIBIT SHP2 ACTIVITY
KR102653681B1 (ko) 2018-07-31 2024-04-03 록쏘 온콜로지, 인코포레이티드 (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의분무-건조된 분산물 및 제제
ES2922314T3 (es) 2018-09-10 2022-09-13 Array Biopharma Inc Compuestos heterocíclicos condensados como inhibidores de cinasa RET
EP3898626A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
WO2020131674A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
CN113543852A (zh) * 2019-03-06 2021-10-22 第一三共株式会社 吡咯并吡唑衍生物
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
JP7420403B2 (ja) 2019-05-08 2024-01-23 ティーワイケー メディシンズ インコーポレーテッド キナーゼ阻害剤として使用される化合物およびその応用
GB201911928D0 (en) 2019-08-20 2019-10-02 Otsuka Pharma Co Ltd Pharmaceutical compounds
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
AR122159A1 (es) * 2020-05-28 2022-08-17 Novartis Ag Inhibidores de mll1 y agentes antineoplásicos
CN114957259A (zh) * 2021-02-25 2022-08-30 南京明德新药研发有限公司 氰基取代的芳香双环类化合物及其应用
US20240309007A1 (en) * 2021-07-01 2024-09-19 Anheart Therapeutics (Hangzhou) Co., Ltd. Crystalline forms of 3-{4-[(2r)-2-aminopropoxy]phenyl}-n-[(1r)- 1-(3-fluorophenyl) ethyl]imidazo[1,2-b]pyridazin-6-amine and salts thereof
CA3254138A1 (en) * 2022-05-18 2023-11-23 Nuvation Bio Inc. PROCESS FOR THE PRODUCTION OF IMIDAZO[1,2-B]PYRIDAZINE 3,6-DISUBSTITUTES COMPOUNDS
CN114989176B (zh) * 2022-07-08 2024-08-27 深圳市新樾生物科技有限公司 咪唑并哒嗪类衍生物及其应用
CN115197115B (zh) * 2022-08-25 2024-11-08 成都金博汇康医药科技有限公司 一种手性5-氧代吡咯烷-3-甲酸的制备方法与应用
CN117659020A (zh) * 2022-09-07 2024-03-08 苏州朗睿生物医药有限公司 一种咪唑并[1,2-b]哒嗪衍生物及其制备方法和用途
AU2023339247A1 (en) 2022-09-07 2025-03-27 Suzhou Langrui Biopharmaceutical Co., Ltd. Macrocyclic imidazo[1,2-b]pyridazine derivative, preparation method therefor, and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008058126A2 (en) * 2006-11-06 2008-05-15 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
AU8664701A (en) 2000-09-01 2002-03-22 Glaxo Group Ltd Oxindole derivatives
WO2002020479A1 (en) 2000-09-01 2002-03-14 Glaxo Group Limited Substituted oxindole derivatives as tyrosine kinase inhibitors
JP2003231687A (ja) 2002-02-04 2003-08-19 Japan Tobacco Inc ピラゾリル縮合環化合物及びその医薬用途
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
JP2007533717A (ja) 2004-04-21 2007-11-22 アストラゼネカ アクチボラグ 化合物
WO2006070943A1 (ja) 2004-12-28 2006-07-06 Takeda Pharmaceutical Company Limited 縮合イミダゾール化合物およびその用途
NZ561145A (en) 2005-02-04 2011-02-25 Astrazeneca Ab Pyrazolylaminopyridine derivatives useful as kinase inhibitors
WO2006087538A1 (en) 2005-02-16 2006-08-24 Astrazeneca Ab Chemical compounds
AU2006215386B2 (en) 2005-02-16 2009-06-11 Astrazeneca Ab Chemical compounds
US20100216798A1 (en) 2005-07-29 2010-08-26 Astellas Pharma Inc Fused heterocycles as lck inhibitors
CN101208339B (zh) * 2005-08-01 2010-12-29 霍夫曼-拉罗奇有限公司 杂环苄基氨基衍生物，它们的制备以及作为药剂的应用
DE102005042742A1 (de) 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
DE102006029447A1 (de) * 2006-06-21 2007-12-27 Bayer Schering Pharma Ag Oxo-substituierte Imidazo[1,2b]pyridazine, deren Herstellung und Verwendung als Arzneimittel
US20100041662A1 (en) 2006-10-30 2010-02-18 Sandrine Ferrand Heterocyclic compounds as antiinflammatory agents
WO2008072682A1 (ja) * 2006-12-15 2008-06-19 Daiichi Sankyo Company, Limited イミダゾ［１，２－ｂ］ピリダジン誘導体
JP2009227599A (ja) * 2008-03-21 2009-10-08 Daiichi Sankyo Co Ltd イミダゾピリダジン誘導体
BRPI0912668A2 (pt) 2008-05-13 2016-01-26 Irm Llc composto e composições como inibidores de quinase
EP2350075B1 (en) 2008-09-22 2014-03-05 Array Biopharma, Inc. Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
KR101147550B1 (ko) * 2009-10-22 2012-05-17 한국과학기술연구원 단백질 키나아제 저해활성을 가지는 2,7-치환된 티에노［3,2-ｄ］피리미딘 화합물
WO2012005299A1 (ja) 2010-07-07 2012-01-12 日本新薬株式会社 Ｒｏｓチロシンキナーゼ阻害剤
WO2012125667A1 (en) 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008058126A2 (en) * 2006-11-06 2008-05-15 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors

Also Published As

Publication number Publication date
ZA201408843B (en) 2016-01-27
KR101781255B1 (ko) 2017-09-22
BR112014029851A2 (pt) 2017-06-27
NO2857404T3 (OSRAM) 2018-01-20
RU2635917C2 (ru) 2017-11-17
JPWO2013183578A1 (ja) 2016-01-28
HUE037221T2 (hu) 2018-08-28
AU2013272701A2 (en) 2015-01-22
LT2857404T (lt) 2017-11-10
JP5814467B2 (ja) 2015-11-17
US20150051190A1 (en) 2015-02-19
SI2857404T1 (sl) 2017-11-30
MX357021B (es) 2018-06-25
CN104520300B (zh) 2016-12-21
CA2874819A1 (en) 2013-12-12
PH12014502721A1 (en) 2015-02-02
US9187489B2 (en) 2015-11-17
US9751887B2 (en) 2017-09-05
SG11201408052WA (en) 2015-01-29
CO7160119A2 (es) 2015-01-15
US20160046639A1 (en) 2016-02-18
RU2014153627A (ru) 2016-08-10
RS56625B1 (sr) 2018-03-30
IL236075A (en) 2017-10-31
WO2013183578A1 (ja) 2013-12-12
HRP20171724T1 (hr) 2018-01-12
ES2648228T3 (es) 2017-12-29
CY1119607T1 (el) 2018-04-04
TWI585088B (zh) 2017-06-01
TW201400486A (zh) 2014-01-01
KR20150014942A (ko) 2015-02-09
IL236075A0 (en) 2015-02-01
EP2857404A4 (en) 2016-01-20
SMT201700539T1 (it) 2018-01-11
HK1207374A1 (en) 2016-01-29
CA2874819C (en) 2017-06-20
CN104520300A (zh) 2015-04-15
AU2013272701A1 (en) 2015-01-15
DK2857404T3 (en) 2017-12-04
PL2857404T3 (pl) 2018-04-30
MX2014014803A (es) 2015-02-12
PT2857404T (pt) 2017-11-23
MY170326A (en) 2019-07-17
EP2857404B1 (en) 2017-08-23
IN2014MN02497A (OSRAM) 2015-07-17
PH12014502721B1 (en) 2015-02-02
NZ702574A (en) 2016-07-29
EP2857404A1 (en) 2015-04-08
BR112014029851B1 (pt) 2023-01-03

Similar Documents

Publication Publication Date Title
AU2013272701B2 (en) Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors
JP7033764B2 (ja) Ｃｄｋ阻害剤としての置換型ヘテロシクリル誘導体
KR102816365B1 (ko) 피라진 화합물 및 이의 용도
EP3168219B1 (en) Pyridone derivative having tetrahydropyranyl methyl group
WO2008081914A1 (ja) Ｐｌｋ１阻害剤としての新規アミノピリミジン誘導体
JP7723666B2 (ja) 環式化合物およびその使用方法
CA2856505A1 (fr) Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR20220028072A (ko) Bet 억제제로서의 헤테로시클릭 화합물
EA030410B1 (ru) Замещенные конденсированные гетероциклы в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных нарушений
JP7584623B2 (ja) キナーゼ阻害活性を有する化合物
TW202122382A (zh) 乙內醯脲衍生物
EP3694331A1 (en) Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
TW202220987A (zh) 經取代雜環化合物及其治療用途
EP4525875A1 (en) Macrocycles as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
EP4141003A1 (en) Pyrazolo[1,5-a]pyridine derivative, preparation method therefor, and composition and use thereof
EP4308096A1 (en) Heteroaroyl amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
HK1207374B (en) Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors
HK40057478B (zh) Hpk1抑制剂及其使用方法
HK40082804A (en) Amide compounds and uses thereof

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 06 JAN 2015

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ IMIDAZO(1,2-B)PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS

FGA Letters patent sealed or granted (standard patent)